3D art   Holy Grail
October 20, 2020

Extended-Release Implants: Re-Vana Therapeutics’ Quest for an Anti-VEGF Grail

During the 38th Congress of the ESCRS, PIE magazine CEO Matt Young had a chance to speak with Michael O’Rourke, CEO of Re-Vana Therapeutics and a 25-year veteran in the ophthalmic industry. Together, they traced Mr. O’Rourke’s winding route to Re-Vana and explored his motivations that led him to the company and its major modus operandi.

Layer of soil
October 20, 2020

Taking OCTA to the Next Level

Optical coherence tomography angiography (OCTA) has stepped into a new tomorrow with the entrance of Canon Medical Xephilio OCT-A1. The…

Discover our fascinating content at issuu